Small Molecules

Paliperidone

Quality Solutions

Category: Hepatic



Authorized Distributor

USP can support your development and manufacturing activities on Paliperidone-based medicines with these existing and upcoming standards.

Official and Proposed Documentary Standards and Associated Physical Materials

MONOGRAPH 1

PALIPERIDONE Official as of 01-May-2020	
USP Paliperidone RS	USP-1491809
USP Paliperidone Resolution Mixture RS	USP-1491795

MONOGRAPH 2

PALIPERIDONE EXTENDED-RELEASE TABLETS Published in PF 48(6) 01-Nov-2022	
USP Paliperidone RS	USP-1491809
USP Paliperidone Related Compound E RS | *NEW*	USP-1491853
PHARMACEUTICAL ANALYTICAL IMPURITIES (PAI)*	
Hydroxybenzoyl Paliperidone	USP-1A04930

INCLUDED GENERAL CHAPTERS

<11> USP REFERENCE STANDARDS
Official as of 01-Nov-2020

<197> SPECTROSCOPIC IDENTIFICATION TESTS
Official as of 01-Sep-2021

<281> RESIDUE ON IGNITION
Official as of 31-Dec-2012

<621> CHROMATOGRAPHY
Official as of 01-Oct-2023

<711> DISSOLUTION
Official as of 01-Nov-2022

<905> UNIFORMITY OF DOSAGE UNITS
Official as of 01-Aug-2023

<921> WATER DETERMINATION
Official as of 01-May-2022

INCLUDED EXCIPIENTS

POLYETHYLENE GLYCOL
Official as of 01-Feb-2020

TITANIUM DIOXIDE
Official as of 01-Jun-2023

FERRIC OXIDE
Official as of 01-Jun-2023

HYPROMELLOSE
Official as of 01-May-2019

SODIUM HYDROXIDE
Official as of 01-Jan-2018

** Pharmaceutical Analytical Impurities (PAI products) are released using a process developed by USP's subject matter experts. The release process is based on internal policies, standard operating procedures, and requirements as defined by USP's Quality Management System. USP is an ISO 9001:2015 certified facility. PAI products are different from official USP Reference Standards. PAI products are not required for compendial compliance.*

01-Apr-2024. For publications related to **Paliperidone** in *PF* online after this date, please visit the integrated *USP-NF/PF* online.